D
Day One Biopharmaceuticals
Biotech & Life Sciences · San Francisco, United States · Founded 2018 · IPO 2021
Cancer drug development comes of age. Follow MoreLess
Day One Biopharmaceuticals focuses on developing innovative treatments for pediatric cancer through a collaborative approach involving multiple stakeholders. The company operates in the biopharmaceutical industry, targeting unmet medical needs in pediatric oncology. Its business model revolves around drug development, clinical trials, and partnerships with healthcare providers and research institutions. Revenue is generated through the commercialization of successful drug candidates and strategic alliances. Day One Biopharmaceuticals serves patients, healthcare providers, and research communities, aiming to improve outcomes for children with cancer.
Keywords: Pediatric cancer, drug development, clinical trials, biopharmaceuticals, oncology, collaborative research, healthcare partnerships, unmet medical needs, commercialization, strategic alliances.
Company overview
Day One Biopharmaceuticals company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2018
- Headquarters
- San Francisco, United States
- Employees
- 252
- Open positions
- 2
- Dealroom signal
- 88.4
- Investment activity
- 1 companies · latest Nov 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Day One Biopharmaceuticals funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Mar 2026 | $2.5B | $2.5B | Servier | ↗ |
| PRIVATE PLACEMENT VCOther financing | Jul 2024 | $175M | — | Wellington Management · Deerfield · Fairmount Funds Management · Frazier Life Sciences | ↗ |
| POST IPO EQUITYOther financing | Jun 2023 | $150M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jun 2022 | $173M | — | Undisclosed | ↗ |
| IPOOther financing | May 2021 | $160M | $160M | Deerfield | — |
| SERIES BOther financing | Feb 2021 | Canaan · BVF Partners · Viking Global Investors · Perceptive Advisors | — | ||
| SERIES AOther financing | May 2020 | Atlas Venture · Access Biotechnology · Canaan | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $158M | 0% | −$142M | -90% |
| 2025 | $158M | +20.6% | −$142M | -90% |
| 2024 | $131M | — | −$235M | -179.1% |
| 2023 | $0 | — | −$223M | — |
| 2022 | $0 | — | −$147M | — |
| 2021 | $0 | — | −$73M | — |
| 2020 | $0 | — | −$14M | — |
Growth signals
Day One Biopharmaceuticals website traffic
Latest recorded traffic for Day One Biopharmaceuticals is 6.9K monthly website visits, down 46.9% over the last three months. Day One Biopharmaceuticals's team grew 14.5% over the past year.
Hiring
Open positions at Day One Biopharmaceuticals
Current openings linked to this company in Dealroom.
Comparisons
Day One Biopharmaceuticals compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Day One Biopharmaceuticals investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Day One Biopharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Day One Biopharmaceuticals has talent and traffic
team presence
In the news
Latest news about Day One Biopharmaceuticals
Recent press, funding announcements, and product moves mentioning Day One Biopharmaceuticals — open to read from the original sources.
Market sentiment
What the market is saying about Day One Biopharmaceuticals
An AI-synthesized read of the highest-engagement posts about Day One Biopharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Day One Biopharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.